San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Telo Therapeutics is raising $10,219,676.00 in new funding. Sources indicate as part of senior management President, Robert Bell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Telo Therapeutics
Telo Therapeutics utilizes a novel precision medicine approach to reverse cancer cell immortality. Developer of cancer therapeutics designed to treat TERT promoter (TERTp) mutant cancers. The company leverages a novel precision medicine approach to inhibit cancer cell immortality by targeting an enzyme called telomerase used by cancer cells in the immortalization process, enabling the medical community and patients to improve associated treatment outcomes.

To learn more about Telo Therapeutics, visit http://telotherapeutics.com/

Contact:
Robert Bell, President
831-234-8510
https://www.linkedin.com/in/rob-bell-b722b213/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved